CRTPF Cardiol Therapeutics Inc. Class A

Cardiol Therapeutics Inc. focuses on the production of pharmaceutical cannabidiol (CBD) products. The company is also developing various therapies for heart diseases, including acute myocarditis and other causes of heart failure. Its lead product is CardiolRx, a pharmaceutically-produced CBD formulation. In addition, it is developing nanotechnology to deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is based in Oakville, Canada.

Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol CT:CRDL.

$2.60    OTCQX
As of 06/14/2021     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  Drug Manufacturers—Specialty &
Index country:  Canada
Country of incorporation:  
IPO date:  01/15/2019
Outstanding shares:  42,856,094
Average volume:  21,626
Market cap:   $113,161,516
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy